← Leaderboards
Ryan A Wilcox
University Of Michigan At Ann Arbor
$8,761,077
Attributed
$9,399,923
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,399,923 · 6
By mechanism
R01$6,224,720 · 3
R37$2,201,963 · 1
K08$893,090 · 1
P30$80,150 · 1
Top collaborators
- Ivan Maillard2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- James Tilford Elder$29,917,141
- David N Reisman$3,409,199
- Linda M McAllister-Lucas$4,836,096
- Dafna D Gladman$1,035,782
- Reshma Jagsi$6,831,946
Others in their field
Top investigators on “Tumor Microenvironment”
- Weiping Zou · University Of Michigan At Ann Arbor$33,281,756
- Howard H Bailey · University Of Wisconsin Madison$30,523,235
- Shuming Nie · Indiana University Bloomington$25,281,578
- Meenhard Herlyn · University Of Pennsylvania$22,542,177
- Rakesh K. Jain · Massachusetts General Hospital$19,480,988
- Timothy Cragin Wang · Columbia University Health Sciences$19,227,767
Research focus
Tumor MicroenvironmentPathogenesisMolecularLymphomaT-LymphocyteT-Cell LymphomaMacrophageResistanceMalignant - DescriptorGeneticSpecimenRefractory DiseaseRecurrenceCellsGenetic TranscriptionGrowthS LymphomaT-Cell DevelopmentCharacteristicsChemotherapyRecurrent DiseaseNon-Hodgkin&AposMutateTranscription Factor
Grant awards (25)
Pacritinib in rel/refr T-cell lymphomas$1,084,365
R01 · FY2025 · CA · contact PI
Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas$621,443
R01 · FY2025 · CA · contact PI
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS$320,391
R37 · FY2025 · CA · contact PI
Cancer Hematopoiesis and Immunology (CHI)$80,150
P30 · FY2025 · CA · contact PI
Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas$656,250
R01 · FY2024 · CA · contact PI
Pacritinib in rel/refr T-cell lymphomas$380,178
R01 · FY2024 · CA · contact PI
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomas$339,008
R01 · FY2024 · CA · contact PI
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS$306,482
R37 · FY2024 · CA · contact PI
Pacritinib in rel/refr T-cell lymphomas$452,633
R01 · FY2023 · CA · contact PI
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomas$349,713
R01 · FY2023 · CA · contact PI
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS$313,987
R37 · FY2023 · CA · contact PI
Pacritinib in rel/refr T-cell lymphomas$632,220
R01 · FY2022 · CA · contact PI
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomas$349,713
R01 · FY2022 · CA · contact PI
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS$320,391
R37 · FY2022 · CA · contact PI
Pacritinib in rel/refr T-cell lymphomas$645,497
R01 · FY2021 · CA · contact PI
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomas$356,850
R01 · FY2021 · CA · contact PI
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS$317,232
R37 · FY2021 · CA · contact PI
Notch and GATA-3 as novel therapeutic targets in T-cell lymphomas$356,850
R01 · FY2020 · CA · contact PI
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS$317,232
R37 · FY2020 · CA · contact PI
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS$306,248
R37 · FY2019 · CA · contact PI
The role of GATA-3 in T-cell lymphomas$178,618
K08 · FY2017 · CA · contact PI
The role of GATA-3 in T-cell lymphomas$178,618
K08 · FY2016 · CA · contact PI
The role of GATA-3 in T-cell lymphomas$178,618
K08 · FY2015 · CA · contact PI
The role of GATA-3 in T-cell lymphomas$178,618
K08 · FY2014 · CA · contact PI
The role of GATA-3 in T-cell lymphomas$178,618
K08 · FY2013 · CA · contact PI